Alcon agrees to acquire LENSAR for up to $430 million

Alcon announced a definitive merger agreement to acquire LENSAR, Inc. for $14.00 per share in cash (approx. $356 million), plus a contingent value right of up to $2.75 per share, for total potential consideration of up to $430 million. The acquisition includes the ALLY Robotic Cataract Laser Treatment System.

“Alcon will purchase all outstanding shares of LENSAR for $14.00 per share in cash (an aggregate implied value of approximately $356 million).”investor.alcon.com

• 1 source
• investor.alcon.comAlcon - Alcon Agrees to Acquire LENSAR, Inc.Mar 24, 2025

Summarized from public sources; check the original articles before acting on it.